Gene Editing Market Size

Global Gene Editing Market Overview

The Gene editing Market size was valued at USD 6.00 billion in 2022 and is projected to grow from USD 7.19 Billion in 2023 to USD 39.79 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 20.9% during the forecast period (2024 - 2032). The growing number of strategic initiatives and increasing funding for genetic research are major factors driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Gene Editing Market Trends

• Growing number strategic initiatives

Genomic editing refers to the strategies and techniques used to modify the genetic information of any living organism. Genome editing involves the modification of genes in multiple locations using recombinant technology, which increases insertion precision and decreases cell toxicity. It is a collection of technologies that allow scientists to alter an organism's DNA. These technologies enable adding, deleting, or modifying genetic material at specific locations within the genome. Rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships to gain a competitive edge and offer advanced treatment options for genomic editing. 

For instance, in April 2022, Thermo Fisher Scientific (US) launched a new GMP-manufactured Gibco CTS TrueCut Cas9 Protein, as high-quality auxiliary materials and documentation are essential, as researchers using genome editing techniques transition from basic research to therapeutic settings. Gibco CTS TrueCut Cas9 Protein is an attractive option for CAR T-cell therapy research employing CRISPR-Cas9 genome editing since it consistently achieves high editing efficiency in all studied cell lines and better than 90% efficiency in human primary T-cells. Similarly, in February 2022, Intellia Therapeutics, Inc. (US) and Regeneron Pharmaceuticals, Inc. (US) announced the positive interim data from an ongoing Phase I clinical study of their lead in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy for Transthyretin (Attr) Amyloidosis). 

Moreover, in February 2022, GenScript Biotech Corporation (US) launched its new CRISPR Genome Editing Cell Line Engineering Service, which enables scientists to create custom cell lines for research and therapeutic applications. The service utilizes GenScript's proprietary CRISPR/Cas9 technology and experienced team of scientists to deliver precise and efficient genome editing. Additionally, it will also expand the company’s position and its commitment to delivering therapeutic applications across the world.

Gene Editing Market Segment Insights

Gene Editing Technology Insights

The Gene editing Market segmentation, based on technology, includes CRISPR, TALEN, ZFN, antisense, and others. The CRISPR segment held the majority share in 2022 in the Gene editing Market revenue due to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is the largest and fastest-growing segment, owing to its wide range of applications in vivo to fix the target gene and ex vivo to rewire & redirect cells for genetic diseases and immuno-oncology autoimmune diseases. Moreover, the major players include AbbVie, Inc. (US), Novartis AG (Switzerland), Bristol Myers Squibb Company (US), Sanofi (France), Vertex Pharmaceuticals Incorporated (US), Regeneron Pharmaceuticals, Inc. (US), and Biogen, Inc. (US). These companies are indulged and highly active in developing CRISPR-based therapeutic products for genetic diseases.

November 2021: GenScript (US) has launched the GenWand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.

Gene Editing Application Insights

The Market segments of Gene editing based on application includes genetic engineering, gene therapy, cell line engineering, and others. The gene therapy segment has dominated the market in 2022 as gene therapy targets the cause of diseases, specifically mutations of genes which causes disorders such as sickle cell disease, inherited eye disorders, transthyretin amyloidosis, multiple myeloma, and cystic fibrosis. According to the American Cancer Society, 1 out of 132 people can get multiple myeloma in the US, which is creating a huge opportunity for biotechnology, pharmaceutical, and contract research organizations of US.

February 2022: Integrated DNA Technologies, Inc (US) launched Alt-R HDR Donor Blocks to advance homology-directed repair genome editing research. IDT's Alt-R HDR Donor Blocks is an improved technique for increasing the rate of homology-directed repair (HDR) in large fragment knock-in investigations

Figure 2: GENE EDITING MARKET, BY APPLICATION, 2022 & 2030 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Gene Editing End User Insights

The Market segmentation of Gene editing is based on biotechnology and pharmaceutical companies, contract research organizations (CROs), and academic & government research institutes. The biotechnology and pharmaceutical companies’ segment have dominated the market in 2021 and is projected to be the fastest-growing segment during the forecast period, 2023-2030. This is due to the increase in funding for gene editing for the development of therapeutic products. Some major companies that raised funding for gene editing platform include Beam Therapeutics (US), which raised USD 135 million on March 2019, Graphite Bio (US), which raised USD 195 million in March 2021, and Caribou Biosciences (US), which raised USD 169 million in March 2021.

September 2022: Integrated DNA Technologies Inc (US) expands customization options for Alt-R Custom CRISPR gRNA Libraries for drug discovery. This expansion allows researchers to quickly assess new therapeutic options.

Gene Editing Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

The North America gene editing market is expected to account for over USD 2 billion in 2022 and is expected to exhibit a 21.19% CAGR during the study period. This is attributed to the increasing of cancer and other genetic disorders, a growing preference for personalized medicine, an increase in private and public sector funding, and rapid advancements in sequencing and gene editing technologies are driving the market for gene editing in the North America region. For instance, in March 2021, Scientists at the University of California (UC), San Francisco, UC Berkeley, and UC Los Angeles received the Food and Drug Administration's approval to jointly launch an early phase, first-in-human clinical trial of a gene correction therapy in sickle cell disease patients using the patient's blood-forming stem cells. Furthermore, according to National Centre for Advancing Translational Sciences reports from June 2022, the National Institutes of Health (NIH) Somatic Cell Gene Editing (SCGE) Programme has given 24 new funds to researchers in the US and Canada. Over the next four years, the SCGE Programme will award a total of USD 89 million in advance gene editing grants.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: GLOBAL GENE EDITING SHARE (%) BY REGION 2022

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe gene editing market is expected to account for the second-largest market share due to technological advancements in healthcare IT such as the use of Artificial intelligence (AI) to manufacture CRISPR systems are driving growth drive the market growth of the gene editing in Europe. Further, the Germany market of gene editing is expected to hold a first place for the market share as well as fastest growing in gene editing, and which is the second position in UK in the European region. Furthermore, Spain market of gene editing will hold the least market share.

The Asia-Pacific gene editing market is expected to grow at a CAGR of 24.03% from 2023 to 2030. This is due to the increasing technological breakthroughs, a thriving biotechnology industry in emerging regions, and the rising prevalence of cancer and other genetic abnormalities. Japan continues to see significant growth in terms of CRISPR technology innovation. For instance, Sanatech Seed (Tokyo), produced the country's first direct consumption gene-edited tomato in 2021. The Japanese ministries in charge, however, announced that the gene-edited tomato will not be regulated as a genetically modified product. New CRISPR research, on the other hand, is expected to drive market expansion in India. Moreover, in 2019, scientists in the country created a unique form of the already popular gene-editing technique, CRISPR-Cas9. The variation has the potential to improve gene editing precision while avoiding unwanted DNA alterations. As a result, these factors are expected to have an impact on the Asia-Pacific gene editing market in the coming years.

The Rest of the World includes the Middle East, Africa, and Latin America. Middle East hold the major market share in middle east and Africa region due to some major factors, such as growing government support, rising public-private partnerships, and increased funding are all contributing to the region's biotechnology industry's growth. In addition, the governments in the region provide tax breaks, cheaper land, incubators, and direct investment, which has encouraged local biotechnology firms to expand their capabilities and capacities in order to contribute to improved healthcare services. The UAE, Saudi Arabia, Oman, and Muscat are the most appealing places for the biotechnology business. This is projected to boost demand for gene editing and speed up market expansion in the future years. In addition, the government and regulatory bodies are providing favorable support to researchers and market companies in order to develop and study gene-based technologies for treatment and immunization of the region's population.

Gene Editing Key Market Players & Competitive Insights

The Gene editing Market is distinguished by the presence of numerous global, regional, and local players catering to the gene editing techniques that are evolving at a rapid pace. Furthermore, the increasing funding for genetic research is further driving the growth of Market of Gene editing during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach and reduce operational costs. For instance, in November 2021, GenScript launched the GenWand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.

The Gene editing Market is extremely competitive, with players competing, partnering, and investing heavily in research and development to gain a significant market share. The market is moderately fragmented with rising competition, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.

Mergers and collaborations were also observed to expand the company's product portfolio, as well as introduce new products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers in the market of gene editing are focusing on developing products with advanced technologies. It is also projected that a rise in the investments for R&D will also boost the market's growth in the upcoming future.

Key Companies in the Gene editing Market Include.

• GE Healthcare (US)


• Thermo Fisher Scientific Inc (US)


• Bio-Rad Laboratories, Inc (US)


• Lonza (Switzerland)


• GenScript (US)


• Horizon Discovery Ltd (UK)


• OriGene Technologies, Inc (US)


• Integrated DNA Technologies, Inc (US)


• New England Biolabs, Inc (US)


• Sangamo Therapeutics (US)

Gene Editing Industry Developments

September 2022: Integrated DNA Technologies Inc (US) expands customization options for Alt-R Custom CRISPR gRNA Libraries for drug discovery. This expansion allows researchers to quickly assess new therapeutic options.

July 2020: Horizon Discovery Group plc (UK) announced an agreement with TrueBinding, Inc a biopharmaceutical company, has signed an agreement of commercial licenses for Horizon’s cGMP compliant CHOSOURCE platform. TrueBinding used the platform for the development and commercialization of many biotherapeutic products for utilize in immuno-oncology and other diseases.

August 2022: Tilray Brands, Inc. launched its comprehensive range of THC and CBD products in Canada.

November 2021: GenScript (US) has launched the Gen Wand Double-Stranded DNA (dsDNA) service for the manufacture of CRISPR knock-in homology-directed repair (HDR) templates in T-cell engineering.

April 2019: GenScript (US) launched a Single-stranded DNA Service for CRISPR-based gene editing. The newly launched service provides researchers with high-quality, pure ssDNA for CRISPR-based gene insertion, with the goal of accelerating the development of gene therapy, cell therapy, and transgenic animal models for cancer research and treatment.

Gene Editing Market Segmentation

Gene Editing Technology Outlook

• CRISPR


• TALEN


• ZFN


• Antisense


• Others

Gene Editing Application Outlook

• Genetic Engineering


• Gene Therapy


• Cell Line Engineering


• Others

Gene Editing End User Outlook

• Biotechnology and Pharmaceutical Companies


• Contract Research Organizations


• Academic & Government Research Institutes

Gene Editing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East and Africa
  
  
  
  • Middle East
  
  
  • Africa